Sanofi Pasteur Inc.

Centers for Disease Control and Prevention

Sanofi Pasteur Sa

Center for Disease Control and Prevention

Other

Jean Lang

Bruno Guy

Véronique Barban

Richard M Kinney

Claire Y H Kinney

Remi Forrat

Alain Bouckenooghe

Rémi Forrat

Nadia Tornieporth

Claire Huang

The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.

Dengue serotype 1 attenuated strain

The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.

Dengue serotype 2 attenuated strain

The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, in which the vaccinal dengue viruses (ii) are administered at least 30 days and at most 1 year after administration of the vaccinal viruses (i).

Method of immunization against the 4 dengue serotypes

The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising

The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising:

Method of immunization against the 4 serotypes of dengue fever

The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.

The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.

Growing community of inventors

Mions, France

Jean Lang